In addition to anticoagulation, cytoreductive therapy with hydroxyurea, peg-interferon alfa or the JAK2 inhibitor, ruxolitinib, is offered to all patients with MPN who develop an SVT to reduce the risk of recurrent thrombosis [94]. Here, JAK2 is linked to myeloproliferative disorder.